- The FDA has signed off Anixa Biosciences Inc's ANIX application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, developed in partnership with Moffitt Cancer Center.
- Anixa Biosciences has an exclusive worldwide license to the technology. The therapeutic product includes engineered T-cells that target the follicle-stimulating hormone receptor (FSHR).
- FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries.
- Related content: Benzinga's Full FDA Calendar
- Price Action: ANIX stock is up 4.76% at $5.50 during the market session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
